Clarithromycin (Biaxin)
What studies of Clarithromycin (Biaxin) found
At a glance, by condition
Long COVID: D Little or no difference
Based on the strongest evidence, the randomised trial (very low certainty): 2 findings, all D.
2 outcomes rated · see each below
ME/CFS: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty), for pain.
1 outcome rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: For long COVID, studies found little or no difference with Clarithromycin (Biaxin). For ME/CFS, Clarithromycin (Biaxin) might help some people, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- Clarithromycin (Biaxin) · ME/CFS is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- Clarithromycin (Biaxin) · Long COVID is hereDLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Long COVID
Symptoms
Breathlessness1 study · 11 people took Clarithromycin (Biaxin) Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: some concerns about bias (RoB 2); one trial of 34 people found no clear difference; a small benefit can't be ruled out.
The randomised trial34 randomised · four weeks · 500 mg, twice daily for four weeks
No clear difference in breathlessness.
The evidence is very uncertain about the effect of clarithromycin (Biaxin) on breathlessness in long COVID. Little or no difference · very low certainty D
- Some concerns about bias (RoB 2)
- One trial of 34 people found no clear difference; a small benefit can't be ruled out
See the 1 study
-
- People in the study
- 34 randomised
- Dose
- 500 mg, twice daily for four weeks
- Outcome
- FVC Forced vital capacity
- Effect
- no clear difference
- Risk of bias
RoB 2: Some concerns
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Daily life and health overall
Daily functioning1 study · 11 people took Clarithromycin (Biaxin) Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: some concerns about bias (RoB 2); one trial of 34 people found no clear difference; a small benefit can't be ruled out; effect size 0.65 (moderate).
The randomised trial34 randomised · four weeks · 500 mg, twice daily for four weeks
No clear difference in daily functioning.
The evidence is very uncertain about the effect of clarithromycin (Biaxin) on daily functioning in long COVID. Little or no difference · very low certainty D
- Some concerns about bias (RoB 2)
- One trial of 34 people found no clear difference; a small benefit can't be ruled out
- Effect size 0.65 (moderate)
How big was the difference?
0.65, moderate. The effect size compares Clarithromycin (Biaxin) with hcq.
See the 1 study
-
- People in the study
- 34 randomised
- Dose
- 500 mg, twice daily for four weeks
- Outcome
- 6MW 6-min walk (6MW) test
- Effect
- no clear difference
- Risk of bias
RoB 2: Some concerns
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
ME/CFS
Pain1 study · 1 (few people) person took Clarithromycin (Biaxin) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all).
Studies with no comparison group1 in the study · 500mg daily (few people)
Pain improved.
The evidence is very uncertain about the effect of clarithromycin (Biaxin) on pain in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
See the 1 study
-
- People in the study
- 1 in the study
- Dose
- 500mg daily
- Outcome
- generalized pain
- Effect
- better
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Side effects
No study of this treatment alone reported side effects we could read.
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
500 mg at the start
- 2Top dose
Most often 500 mg (2 of 2 studies)
Doses across 2 studies
500 to 500 mg.
Each study’s dose, as printed
- 500mg daily Clarithromycin for the Relief of Pain in a Patient with Chronic Fatigue Syndrome and Fibromyalgia: A Case Report (2013)
- 500 mg, twice daily for four weeks Efficacy of Hydroxychloroquine versus Clarithromycin in the Improvement of Dyspnea and Cough in Patients after the Treatment of Acute-Phase COVID-19 (2023)
All papers
- Efficacy of Hydroxychloroquine versus Clarithromycin in the Improvement of Dyspnea and Cough in Patients after the Treatment of Acute-Phase COVID-192023 · randomised trial · 34 randomised
Summary
This study enrolled 34 patients aged 20-50 years in the recovery phase of COVID-19 who still had symptoms such as shortness of breath, cough, and pulmonary involvement on CT two weeks after treatment ended at Rasool Akram Hospital, Tehran, Iran. Patients were divided into three groups: HCQ 200 mg twice daily for four weeks (n=12), clarithromycin 500 mg twice daily for four weeks (n=11), and placebo similar to the last two groups (n=11). Patients were followed two and four weeks after starting treatment. Dyspnea and cough were assessed with the Medical Research Council and visual analog scale (VAS), with laboratory tests, 6-min walk test, and spirometry also checked. After treatment, VAS cough was 0.76 with HCQ, 0.02 with clarithromycin, and 1.15 with placebo; clarithromycin versus placebo had SMD -1.02 (95% CI -1.90 to -0.11; P=0.080), reported as not statistically significant. HCQ versus clarithromycin had SMD 0.67 (95% CI -0.18 to 1.50; P=0.29). Patients receiving HCQ had a 64% chance of reducing shortness of breath versus placebo (RR=0.36); clarithromycin had a 40% lower chance (RR=0.60). FVC was 80.81, 78.34, and 81.32; FEV1 was 90.47, 90.57, and 90.47, with no differences observed. 6MW was 583.77, 635.88, and 585.46 meters. The text does not report side effects or withdrawals. Authors state a small sample size, single center, and limited resources hindered follow-up.
- Clarithromycin for the Relief of Pain in a Patient with Chronic Fatigue Syndrome and Fibromyalgia: A Case Report2013 · case report · 1 in the study
Summary
This case report describes one 36-year-old woman with fibromyalgia and a 15-year history of chronic fatigue syndrome at a tertiary academic medical center outpatient MSK clinic. She was started on Lyrica, Trazodone, and physical therapy; Lyrica was later discontinued and she was started on low-dose Naltrexone. She was placed on Clarithromycin again, 500mg daily; no comparison group was reported. The paper reports that she had noted significant improvement of her generalized pain while taking Clarithromycin, and that the pain returned when it was stopped. The report also states that her fatigue has not completely resolved, that she now only takes Advil for pain occasionally, rest and ice, and that she sleeps about 8 hours per night. Harms were not reported; withdrawals for harms were not reported. The authors conclude that Clarithromycin seemed to play a role in the relief fibromyalgia-associated pain in a patient who also had chronic fatigue syndrome. They do not state limitations.
- Severe ME in Children.2020 · combination: given with other treatments
Summary
The paper presents a series of case reports of individual cases to illustrate clinical presentation and general principles of management of severe paediatric ME/CFS. The author writes that there is very limited data on patients who are very severe, housebound or bedbound. No number of patients, clinic setting, comparison group or formal outcome measures are reported. Treatments described across the cases include nasogastric or nasojejunal tube feeding, intramuscular immunoglobulin monthly for 12 months, amitriptyline, carbamazepine, clarithromycin, doxycycline, opiates, a urinary catheter, active physiotherapy for three months and Tender Loving Care. The paper reports that one case made a very slow recovery, with tube feeding stopped after 3 years, and was operating at 95% of normal 20 years later; another made a full recovery by the end of two years; another recovered completely within 12 months after clarithromycin was changed to doxycycline and had no relapses at follow up 12 years later; and Case A made a full spontaneous recovery. Case B received active physiotherapy for three months, deteriorated further and remained severely affected 20 years later. Case C died. Harms include a traumatic hospital experience, a convulsive myoclonic jerk from noise and sensory overload. The author states that one should not draw too many conclusions from one case.